The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group

Follicular lymphoma (FL) is considered to be an incurable disease, but most patients can survive for many years. [1] The indolent course of the disease is typically characterized by an initial response to the induction of immunochemotherapy but the disease typically relapses within several years. Many clinical trials have shown the clinical benefits of the addition of rituximab to the first-line chemotherapy regimen in terms of a better progression free survival (PFS) and overall survival rate (OS) [2,3].

Source: Leukemia Research - August 31, 2018 Category: Hematology Authors: David Belada, Vit Prochazka, Andrea Janikova, Vit Campr, Petra Blahovcova, Robert Pytlik, Alice Sykorova, Pavel Klener, Katerina Benesova, Jan Pirnos, Juraj Duras, Heidi Mocikova, Marek Trneny Tags: Research paper Source Type: research